School of Food and Biological Engineering, Xihua University, Chengdu, 610039, China.
School of Health Management, Xihua University, Chengdu, 610039, China.
J Ethnopharmacol. 2024 May 23;326:117987. doi: 10.1016/j.jep.2024.117987. Epub 2024 Feb 27.
Paeoniae Radix Rubra (PRR) is the dried root of Paeonia lactiflora Pall, which has been widely used to anti-thrombotic, lipid-lowering, anti-spasmodic, antioxidant, antibacterial, hepatoprotective, and anti-tumor in Chinese clinical practice. Recent research has demonstrated that PRR plays a significant anti-tumor role in animal models of tumor-bearing.
There has not been the evaluation of the anti-tumor effects of PRR. This study conducts a meta-analysis to assess the anti-tumor efficacy of PRR on animal models, providing scientific evidence for clinical application of PRR in the adjuvant therapy of tumors.
English databases (PubMed, The Cochrane Library, Embase, and Web of Science) and Chinese databases (CNKI, WanFang, SinoMed, CTSJ-VIP) were used to search all pertinent animal studies investigating the anti-tumor effects of PRR and its extracts. The quality of the included studies was evaluated using the SYRCLE animal experiment risk assessment tool, and statistical analysis was carried out using Revman 5.3 software. Egger's test and funnel plots were used to assess potential publication bias in the studies.
The initial search produced a total of 3905 potentially pertinent studies, and 24 studies met the inclusion criteria. These studies included animal tumor models of hepatocellular carcinoma, lung cancer, sarcoma, bladder cancer, leukemia, colon cancer, glioblastoma, and pancreatic cancer. The meta-analysis findings demonstrated that both PRR and its extracts significantly inhibited tumor growth in animals. Compared with the control group, PRR substantively inhibited tumor volume (SMD, -3.09; 95% CI, [-4.05, -2.13]; P < 0.0001), reduced tumor weight (SMD, -1.08; 95% CI, [-1.37, -0.78]; P < 0.0001), decreased tumor number (SMD, -2.16; 95% CI, [-3.45, -0.86]; P = 0.001), and prolonged the survival duration time (SMD, 0.97; 95% CI, [0.23, 1.71]; P = 0.01) on the experimental animals.
PRR displayed a potential therapeutic efficacy on eight tumors in animal models including hepatocellular carcinoma, lung cancer, sarcoma, bladder cancer, leukemia, colon cancer, glioblastoma, and pancreatic cancer. However, the quality and quantity of included studies may affect the accuracy of positive results. In the future, more high-quality randomized controlled animal experiments are need for meta-analysis.
赤芍（PRR）是芍药 Paeonia lactiflora Pall 的干燥根，在中国临床实践中已广泛用于抗血栓、降血脂、抗痉挛、抗氧化、抗菌、保肝和抗肿瘤。最近的研究表明，PRR 在荷瘤动物模型中发挥着重要的抗肿瘤作用。
目前尚未对 PRR 的抗肿瘤作用进行评估。本研究通过荟萃分析评估 PRR 对动物模型的抗肿瘤疗效，为 PRR 在肿瘤辅助治疗中的临床应用提供科学依据。
使用英文数据库（PubMed、The Cochrane Library、Embase 和 Web of Science）和中文数据库（CNKI、万方、中国生物医学文献服务系统、维普中文期刊服务平台）检索所有关于 PRR 及其提取物抗肿瘤作用的相关动物研究。使用 SYRCLE 动物实验风险评估工具评估纳入研究的质量，并使用 RevMan 5.3 软件进行统计分析。使用 Egger 检验和漏斗图评估研究中的潜在发表偏倚。
最初的搜索共产生了 3905 篇潜在相关的研究，其中 24 篇符合纳入标准。这些研究包括肝癌、肺癌、肉瘤、膀胱癌、白血病、结肠癌、胶质母细胞瘤和胰腺癌的动物肿瘤模型。荟萃分析结果表明，PRR 及其提取物均能显著抑制动物的肿瘤生长。与对照组相比，PRR 显著抑制肿瘤体积（SMD，-3.09；95%CI，[-4.05，-2.13]；P<0.0001），降低肿瘤重量（SMD，-1.08；95%CI，[-1.37，-0.78]；P<0.0001），减少肿瘤数量（SMD，-2.16；95%CI，[-3.45，-0.86]；P=0.01），并延长实验动物的生存时间（SMD，0.97；95%CI，[0.23，1.71]；P=0.01）。
PRR 对包括肝癌、肺癌、肉瘤、膀胱癌、白血病、结肠癌、胶质母细胞瘤和胰腺癌在内的八种肿瘤的动物模型显示出潜在的治疗效果。然而，纳入研究的质量和数量可能会影响阳性结果的准确性。未来需要更多高质量的随机对照动物实验进行荟萃分析。
